Determination of stavudine in human plasma and urine by high-performance liquid chromatography using a reduced sample volume

• Published in: Journal of chromatography. B, Biomedical sciences and applications Biomedical sciences and applications, 2000-09, Vol.746 (2), p.183-189
• Main Authors: Sarasa, Marı́a, Riba, Neus, Zamora, Laura, Carné, Xavier
• Format: Article
• Language: English
• Subjects: Analysis; Anti-HIV Agents - blood; Anti-HIV Agents - pharmacokinetics; Anti-HIV Agents - urine; Biological and medical sciences; Chromatography, High Pressure Liquid - methods; Female; General pharmacology; Humans; Infant, Newborn; Medical sciences; Pharmacology. Drug treatments; Pregnancy; Reproducibility of Results; Reverse Transcriptase Inhibitors - blood; Reverse Transcriptase Inhibitors - pharmacokinetics; Reverse Transcriptase Inhibitors - urine; Sensitivity and Specificity; Stavudine; Stavudine - blood; Stavudine - pharmacokinetics; Stavudine - urine
• ISSN: 0378-4347; 1387-2273
• DOI: 10.1016/S0378-4347(00)00324-8

Sensitive high-performance liquid chromatographic assays have been developed for the quantification of stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T) in human plasma and urine. The methods are linear over the concentration ranges 0.025–25 and 2–150 μg/ml in plasma and urine, respectively. An aliquot of 200 μl of plasma was extracted with solid-phase extraction using Oasis ® cartridges, while urine samples were simply diluted 1/100 with HPLC water. The analytical column, mobile phase, instrumentation and chromatographic conditions are the same for both methods. The methods have been validated separately, and stability tests under various conditions have been performed. The detection limit is 12 ng/ml in plasma for a sample size of 200 μl. The bioanalytical assay has been used in a pharmacokinetic study of pregnant women and their newborns.